Dr David Skurnik
LinkedIn logo Assitstant Professor in Medicine 

MTAnalytics United States

At MTAnalyics we focus on increasing statistical power to improve the detection of weak association signals between variables. By contrast to data mining, we are using statistical tools that allow us to provide power and p-values in our analysis. In other words, we are specific alike classic statistics and sensitive as data mining.

For clinical trials, we significantly reduce the sample size while keeping the same power. Fundamentally, you will be able to decrease your sample size by 30% while keeping the same p-value, the same statistical power. Obvious main consequences: gain of time, of money, resources etc…

Our work addresses these challenges and aims at providing rationale to design and perform statistical analysis when large amount of data are available. We are not competing with the companies allowing to hire patients faster. We come into play before the design of the trial even started to allow for the design of a trial to include a reduced sample size. We focus in particular on increasing statistical power in order to reduce sample size or improving the detection of weak association between variables by leveraging all available information.

In big data, we provide insights into data sets, predict outcomes, increase the strengths of the models used to explain an outcome based on the analysis of a dataset. Again, the basis of our approach is to improve the detection of weak signals.

Any classical approach is able to detect a strong signal, but when an outcome is not explained (or associated) to one major or a few big variables but by a multiple of weak signals, you need a model to link and find these weak signals, in order to explain a maximum of your outcome.

With our approach, we are able to explain significantly more of the outcome, by reinforcing the models, by finding weak associations hidden in the data sets and missed by the other approaches. In other words, we detect associations that others cannot.

Mr Gary Goldmuntz
co-founder 

Nano3D Biosciences, Inc. United States

Biomedical research is gravitating towards 3D cell culture models and tissue printing. At n3D, we sell kits and services for 3D cell culture. Our core technology is the magnetization of cells, which can then be directed using magnetic forces. In this manner, we can either levitate or bioprint cells. These cultures are faster to assemble than other systems and easier to handle with magnets without losing samples. Check out our products and ourservices for more information on our technology, and how we can help you!

Website:
www.n3dbio.com
Mr Glauco Souza
President and CSO 

Nanotech Plus, LLC United States

Nanotech Plus, LLC is a consulting firm focused on the commercialization of advanced materials. Our clients include Fortune 500 companies to startups as well as government agencies. Whether you need information ranging from a potential market for a new product to an assessment of a patent portfolio, we can help. In our 5 year history, we have had a diverse group of clients with a diverse set of needs- but we've been able to satisfy them all.

Specialties

consulting, marketing patent assessment, due diligence

Mr Sam Brauer
Principal 

New York BioLabs United States

Our mission is to help create the next generation of powerhouse biotech companies by providing entrepreneurs and innovative life-sciences startups with the space and resources they need to test out, challenge, and nurture early ideas. In order to create a fertile environment in which visionaries can thrive, we aim to:

  • Foster a collaborative atmosphere that allows thought-sharing and creative exchange

  • Offer best-in-class infrastructure to enable the unfettered practice of science

  • Promote cost efficiencies through sharing of many services such as permitting, purchasing, maintenance, IT, and security

  • Anticipate needs and roadblocks for entrepreneurs in order to provide the smoothest possible path to growth

  • Create a bioinnovation ecosystem that fosters collegial interactions among industry, investors, government, and academia

Dr Nicole McKnight
LinkedIn logo Director 

New York Structural Biology Center United States

The New York Structural Biology Center, NYSBC, is an organization of 9 eminent academic research institutions. Founded in 1999, NYSBC is a not-for-profit consortium that provides advanced resources in structural biology to its members and outside users. The Center manages two facilities, its main facility in Manhattan and a crystallography facility at the National Synchrotron Light Source (NSLS and NSLS-­‐II) at Brookhaven National Laboratories (BNL) on Long Island. NYSBC is a global leader in structural biology with unsurpassed instrumentation and expertise whose services include high throughput gene-to-­structure determination, X-­ray crystallography, NMR spectroscopy, Cryo-­electron microscopy and Protein Production.

New York Structural Biology Center United States

Founded in 1999 by nine eminent New York academic institutions, the New York Structural Biology Center (NYSBC) is one of the world’s leading centers for structural biology, a field critical for rationally-designed drugs.

Based in Manhattan, we are the only facility in the  US  that  provides  all  three major technologies used in biomolecule structure determination: X-ray crystallography, NMR spectroscopy and cryo-electron microscopy, as well as high quality protein production.

NYSBC works with academic scientists, biopharmaceutical companies and the US government, on a membership or fee-for-service basis, on projects ranging from protein production to structure determination and drug design.

To find out more, please call us (212-939-0660) or visit our website (www.nysbc.org).

Website:
www.nysbc.org
Dr Rui Galvao
LinkedIn logo Senior Business Development Officer 

New York University United States

About NYU

More than 175 years ago, Albert Gallatin, the distinguished statesman who served as secretary of the treasury under Presidents Thomas Jefferson and James Madison, declared his intention to establish "in this immense and fast-growing city ... a system of rational and practical education fitting for all and graciously opened to all." Founded in 1831, New York University is now one of the largest private universities in the United States. Of the more than 3,000 colleges and universities in America, New York University is one of only 60 member institutions of the distinguished Association of American Universities

Ms Sadhana Chitale
Director, Life Sciences/Technology Transfer 

New York University United States

Professor Tommy Lee
Director 

New York University School of Medicine United States

YU School of Medicine is one of the nation’s preeminent academic institutions. For more than 150 years, we have trained thousands of physician-scientists who have helped to shape the course of medical history and enrich the lives of countless people. Through medical education, scientific research, and patient care, we continue to demonstrate our deep, abiding commitment to improving the human condition.

The percentage of NYU graduates who are members of medical school faculties is among the highest in the nation. For most of them, an invaluable part of that training was their service at Bellevue Hospital, one of the nation’s finest municipal hospitals, where NYU physicians have provided clinical and emergency care to
New York City’s poor and immigrant populations for more than a century.

As part of a “biomedical corridor” extending from 23rd to 34th Streets along Manhattan’s East River Drive, our institution is guided by the promise of “translational medicine,” in which scientific discoveries are urgently translated into innovative treatments for patients. To create an environment worthy of rapid medical advances, we are constructing new research and clinical facilities. These state-of-the-art facilities will serve as the home for our physician-scientists who are the intellectual foundation of the School. In addition, we are recruiting a new generation of scholars and teachers who have established national and international reputations. And we are admitting some of the nation’s best and brightest students, many of whom will become tomorrow’s leaders in the medical profession.

Your focus and ours is whether NYU is the right place to pursue your medical education. We hope that this website captures the spirit of the educational enterprise at NYU, as well as the experience of studying medicine in the heart of New York City.

Nadim Shohdy
Director, Drug Discovery Partnerships